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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent cause of complicated skin and skin
structure infections (cSSSI). Patients with MRSA require different empiric treatment than those with non-MRSA
infections, yet no accurate tools exist to aid in stratifying the risk for a MRSA cSSSI. We sought to develop a simple
bedside decision rule to tailor empiric coverage more accurately.
Methods: We conducted a large multicenter (N=62 hospitals) retrospective cohort study in a US-based database
between April 2005 and March 2009. All adult initial admissions with ICD-9-CM codes specific to cSSSI were
included. Patients admitted with MRSA vs. non-MRSA were compared with regard to baseline demographic, clinical
and hospital characteristics. We developed and validated a model to predict the risk of MRSA, and compared its
performance via sensitivity, specificity and other classification statistics to the healthcare-associated (HCA) infection
risk factors.
Results: Of the 7,183 patients with cSSSI, 2,387 (33.2%) had MRSA. Factors discriminating MRSA from non-MRSA
were age, African-American race, no evidence of diabetes mellitus, cancer or renal dysfunction, and prior history of
cardiac dysrhythmia. The score ranging from 0 to 8 points exhibited a consistent dose–response relationship. A
MRSA score of 5 or higher was superior to the HCA classification in all characteristics, while that of 4 or higher was
superior on all metrics except specificity.
Conclusions: MRSA is present in 1/3 of all hospitalized cSSSI. A simple bedside risk score can help discriminate the
risk for MRSA vs. other pathogens with improved accuracy compared to the HCA definition.
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Background
Although rates of serious infections with pathogens such
as methicillin-resistant Staphylococcus aureus (MRSA)
have been rising over recent years [1], there is encour-
aging news from the Centers for Disease Control and
Prevention (CDC) indicating that this rise may be abat-
ing for healthcare-associated pathogens, though not for
community-acquired ones [2]. Much of the emergent re-
sistance can be attributed to selection pressures created
by overuse of broad-spectrum antibiotics [3,4]. Empiric
treatment of an infection becomes a balancing act for
physicians concerned with containing the spread of re-
sistance vs. not covering broadly enough, impacting clin-
ical response and potentially outcomes [5-11].
Complicated skin and skin structure infections (cSSSI)
are a common reason for hospitalization. S. aureus-
related cellulitis hospitalizations, for example, have risen
4-fold in a recent 6-year period to over 90,000 dis-
charges [1], and MRSA is the cause of cellulitis in 15%
of all cSSSI cases [12]. While there is indirect evidence
that inappropriate choice of empiric therapy may impact
clinical outcomes among patients hospitalized with
cSSSIs [12], this has not been confirmed broadly [11].
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However, what does appear to be affected by the initial
antibiotic choice is the duration of hospitalization [11],
an outcome of utmost importance given the fiscal con-
straints in the healthcare system. For this reason, an
early risk stratification tool for the presence of MRSA
infection would be useful because a) prompt targeted
treatment would balance appropriate spectrum coverage
with concerns for resistance emergence and b) conven-
tional laboratory testing takes 48–72 h to yield culture
results.
We set out to compare current epidemiology and out-
comes of patients hospitalized with MRSA cSSSI to
those hospitalized with non-MRSA. Based on these dif-
ferences, we developed and validated a clinical decision




This retrospective cohort study used data collected from
62 hospitals in the Health Facts electronic medical rec-
ord database (Cerner Corporation, Kansas City, MO).
Health Facts is a database built from hospitals’ compre-
hensive clinical records including pharmacy, laboratory,
admission, and billing information from all affiliated pa-
tient care locations. All admissions, medication orders,
and laboratory orders and collections are labeled with
date and time. Hospital billing/registration and encoun-
ter data are integrated with clinical information relating
to the drugs dispensed and the results of diagnostic la-
boratory testing. Cerner Corporation has established
Health Insurance Portability and Accountability Act
(HIPAA)–compliant operating policies and procedures
using statistical methods to establish de-identification.
Cohort selection
Included patients were at least 18 years of age, hospita-
lized between April 2005 and March 2009, and met our
diagnostic criteria in one of two ways: 1) Admission had
a primary diagnosis from Additional file 1: Appendix A
OR 2) Admission had a secondary diagnosis from Add-
itional file 1: Appendix A, a primary diagnosis of sepsis
(International Classification of Diseases, Clinical Modifi-
cation [ICD-9-CM] codes 020.2, 038.xx, 790.7, 995.91,
or 995.92), and no other source of infection documented
by ICD-9-CM code. Patients were also required to have
both 1) collection of a blood or skin culture that was
positive for bacteria and 2) treatment with any intraven-
ous (IV) antibiotic within 48 h of presentation. The posi-
tive index culture had to contain at least one organism
that was not considered to be a skin contaminant. Cul-
tures of organisms considered to be skin contaminants
(Corynebacterium/diphtheroids, Staphylococcus epider-
midis or other coagulase-negative Staphylococcus sp.,
Propionibacterium, Streptococcus viridians, Aerococcus
spp, Bacillis spp [except B. anthracis]) were excluded
from the cohort. Other exclusions were pregnancy or
complications of childbirth, major trauma, and inpatient
admission within 30 days with primary or secondary
diagnosis of cSSSI (Additional file 1: Appendix A).
Measures
Microbiology results were prioritized to reduce the like-
lihood of colonizing microorganisms, though included
patients could have polymicrobial infection. For patients
with multiple culture results within the 48-hour time-
frame, cultures from a skin source or venipuncture were
prioritized over blood cultures drawn from a line, and
certain sources of skin cultures with a high risk of con-
tamination such as “swabs” were excluded. Lower ex-
tremity infections were identified using the 4th digit of
the ICD-9-CM diagnosis code and/or the anatomic loca-
tion of the skin culture, if present. Healthcare-associated
(HCA) infection was defined based on the presence of at
least one of the following factors: 1) admission from a
chronic care facility, or 2) hospitalization within the pre-
vious 180 days or recent outpatient surgery, or 3)
hemodialysis within 90 days or end-stage renal disease
(ESRD) diagnosis code, or 4) chronic dependence on
mechanical ventilation. Impaired immune function,
based on specific ICD-9-CM codes and/or medication
use, was examined separately. Chronic comorbidities
present during admission or 12 months prior were iden-
tified by ICD-9-CM codes; baseline (within 48 hours of
admission) laboratory variables were also recorded.
Organ dysfunction measures at or before the time of the
index culture were designed to be consistent with a
Sepsis-related Organ Failure Assessment (SOFA) score
equal to 2 or greater [13]. These included cardiovascular,
respiratory, hepatic, hematologic, and renal dysfunction.
Unadjusted hospital mortality served as the primary
endpoint, while length of stay (LOS) among survivors
was the secondary outcome.
Based on statistical and clinical considerations, we
built and explored the usefulness of a simple summary
score to identify infection with MRSA vs. a non-MRSA
organism.
Analyses
Our aim was to develop a simple summary score to be
used at the bedside to serve as a clinical decision tool to
distinguish patients with MRSA from those with an in-
fection with another pathogen (non-MRSA). To accom-
plish this, we first compared patients admitted with
MRSA to those with non-MRSA with regard to baseline
demographic, clinical and hospital characteristics. To
test for differences between groups, we used t-tests for
continuous variables and the chi square test or Fisher’s
Zilberberg et al. BMC Infectious Diseases 2012, 12:154 Page 2 of 9
http://www.biomedcentral.com/1471-2334/12/154
exact test for categorical variables. When constructing
the summary scores, potential covariates were included
in the models if they reached significance at alpha=0.2 in
the univariate analyses, or if a priori they were deter-
mined to have clinical relevance (Additional file 1: Ap-
pendix B) [14]. Variables were included only if they were
present on admission or could be known within the first
24 hours of admission. The rationale for the 24-hour
window was that inappropriately targeted empiric anti-
microbial coverage within this time frame is associated
with worsened outcomes [5-11]. In the selection of la-
boratory variables, we only considered tests for which at
least 95% of values were obtained within 24 hours of
admission.
A split sample approach was used, whereby 80% of the
patients were randomly selected for model development
and the remaining 20% were used for model validation.
To identify the most predictive variables of MRSA vs.
non-MRSA infection, we constructed a series of back-
ward stepwise logistic regression models on boot-
strapped with replacement (simulated) datasets from the
development set and created a frequency table indicating
the number of times the eligible predictors entered these
stepwise regression models. The variables appearing
most frequently were then considered for inclusion in
the final summary score [15]. The score was designed a
priori to rely on no more than 5 predictors for ease of
use in clinical practice (which compelled us to exclude
highly predictive but rare variables from the final
model). The final model’s predictors were included in a
logistic regression model and the coefficients were fully
standardized to a unit variance. The predictors in the
summary score were then assigned integer-valued
weights proportional to these standardized coefficients.
We calculated the prevalence of MRSA infection at
every score value in the development cohort and com-
pared these results to the prevalence in the validation
cohort to assess calibration. A simple, overall classifica-
tion rate is often misleading when the overall prevalence
of a condition is either quite high or low. To better as-
sess the predictive ability of the models, we calculated
specificities and sensitivities at various threshold levels
of the score(s) to derive likelihood ratios. With these sta-
tistics, we constructed Fagan’s nomograms to show a
patient’s posterior probability of having MRSA if the
score was above or below a particular threshold (i.e.,
being above a threshold level was analogous to a positive
“test”) [16].
To augment usefulness at the bedside and to bench-
mark the score against the HCA risk factors, an add-
itional assessment of score characteristics was done
calculating sensitivity, specificity, positive and negative
predictive values for each threshold score along the
scale. These characteristics were then compared to the
performance of the HCA definition as a way to discrim-




Among the 7,183 patients hospitalized with cSSSI,
MRSA was cultured in 2,387 (33.2%), with the remainder
(n=4,796) infected with non-MRSA (Table 1). Compared
to patients with non-MRSA, those with MRSA were
younger, less likely to be Caucasian, more likely to be on
the medical service, and had lower comorbidity burden.
Additionally, fewer of them had any risk factors for
HCA infection (MRSA 32.6%, non-MRSA 36.8%,
p<0.001) or a history of immune suppression (MRSA
22.9%, non-MRSA 28.9%, p<0.001).
Outcomes
Unadjusted hospital mortality was lower in the MRSA
(3.0%) than the non-MRSA (4.7%) group, p<0.001. Simi-
larly, the median hospital LOS was shorter in the MRSA
(4.2 days) than in the non-MRSA (5.7 days) group, p
<0.001.
MRSA prediction score
The MRSA score was constructed on a random sample
of 80% of the patients (development set, N=5,736) and
validated on the remaining 20% (validation set,
N=1,447). Factors differentiating MRSA infection from
other organisms, based on the logistic regression,
resulted in a score ranging from 0 to 8 points (Table 2).
Those factors and their corresponding points were: age
(range 0–3 points), African-American race (1 point), no
evidence of diabetes mellitus (1 point), cancer (1 point)
or renal dysfunction (1 point), and prior history of car-
diac dysrhythmia (1 point). Increasing scores corre-
sponded well to increased likelihood of MRSA infection
in both development and validation cohorts (Figure 1).
Table 3 presents the prevalence of actual MRSA iso-
lates among patients with a particular score. While ap-
proximately 20% of all cases of MRSA had the score of
0–1, among those scoring 7–8 nearly 2/3 had the organ-
ism. Between these extremes, the score exhibited a con-
sistent dose–response relationship.
We additionally examined the test characteristics of
various score thresholds for detecting MRSA, and com-
pared those to the HCA definition (Table 4). A MRSA
score of 5 or higher turned out to be superior to the
HCA classification in all characteristics, while that of 4
or higher was superior on all metrics except specificity.
Using the threshold of 5 as an example for the score, if a
clinician is most interested in excluding the probability
of MRSA, the negative predictive value (the probability
of scoring below 5 given that there was no MRSA
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Frequency (%) Frequency (%) Frequency (%)
Age in years, mean (SD) 56.5 (19.4) 51.5 (19.6) 59.0 (18.8) <0.001
18-44 2066 (28.8%) 956 (40.1%) 1110 (23.1%)
45-54 1285 (17.9%) 463 (19.4%) 822 (17.1%)
55-64 1275 (17.8%) 335 (14%) 940 (19.6%)
65-74 971 (13.5%) 229 (9.6%) 742 (15.5%)
75-84 947 (13.2%) 258 (10.8%) 689 (14.4%)
>85 639 (8.9%) 146 (6.1%) 493 (10.3%)
Gender
Male 3966 (55.2%) 1364 (57.1%) 2602 (54.3%) 0.013
Female 3216 (44.8%) 1022 (42.8%) 2194 (45.7%)
Unknown 1 (0%) 1 (0%) 0 (0%)
Race
Caucasian 5314 (74%) 1709 (71.6%) 3605 (75.2%) <0.001
African American 1507 (21%) 572 (24%) 935 (19.5%)
Other/Unknown 362 (5%) 106 (4.4%) 256 (5.3%)
Insurance type
Commercial 963 (13.4%) 331 (13.9%) 632 (13.2%) <0.001
Medicare 1741 (24.2%) 444 (18.6%) 1297 (27.0%)
Medicaid 456 (6.3%) 161 (6.7%) 295 (6.2%)
Self-paid 203 (2.8%) 86 (3.6%) 117 (2.4%)
Other/Unknown 3820 (53.2%) 1365 (57.2%) 2455 (51.2%)
Patient type
Surgical 1983 (27.6%) 613 (25.7%) 1370 (28.6%) 0.010
Medical 5200 (72.4%) 1774 (74.3%) 3426 (71.4%)
Year of discharge
2005 875 (12.2%) 265 (11.1%) 610 (12.7%) 0.380
2006 1648 (22.9%) 552 (23.1%) 1096 (22.9%)
2007 1935 (26.9%) 660 (27.6%) 1275 (26.6%)
2008 2250 (31.3%) 750 (31.4%) 1500 (31.3%)
2009 475 (6.6%) 160 (6.7%) 315 (6.6%)
Hospital Characteristics
Census region
Northeast 2887 (40.2%) 818 (34.3%) 2069 (43.1%) <0.001
Midwest 1897 (26.4%) 573 (24.0%) 1324 (27.6%)
South 2123 (29.6%) 923 (38.7%) 1200 (25%)
West 276 (3.8%) 73 (3.1%) 203 (4.2%)
Urban setting (vs. rural) 7171 (99.8%) 2385 (99.9%) 4786 (99.8%) 0.358
Hospital bed size
6-99 371 (5.2%) 166 (7.0%) 205 (4.3%) <0.001
100-199 980 (13.6%) 316 (13.2%) 664 (13.8%)
200-299 1751 (24.4%) 557 (23.3%) 1194 (24.9%)
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present) was 72.3%. This represents a 12% relative im-
provement over the negative predictive value of the
HCA definition (64.3%).
A Bayesian analysis was performed via Fagan’s nomo-
gram on the validation set (Figure 2). The threshold
classification results are based on the scores of 3 (T-3), 5
Table 1 Patient demographics and hospital characteristics (Continued)
300-499 2116 (29.5%) 663 (27.8%) 1302 (27.1%)
≥500 1965 (27.4%) 685 (28.7%) 1431 (29.8%)
Teaching (vs. non-teaching) 4412 (61.4%) 1406 (58.9%) 3006 (62.7%) 0.002
Charlson comorbidity index, mean (SD) 1.8 (2.1) 1.5 (2.0) 2.0 (2.1) <0.001
Risk factors for healthcare-associated infection (any) 2543 (35.4%) 777 (32.6%) 1766 (36.8%) <0.001
Recent hospital discharge (within 180 days) or recent outpatient surgery 2,255 (31.4%) 702 (29.4%) 1,553 (32.8%) 0.011
Outpatient hemodialysis within 90 days or ESRD patient 591 (8.2%) 176 (7.4%) 415 (8.7%) 0.063
Admission from a chronic care facility 369 (5.1%) 105 (4.4%) 264 (5.5%) 0.046
Mechanical ventilation/Dependence on respirator 48 (0.7%) 12 (0.5%) 36 (0.8%) 0.224
Immunosuppression Factors (any below), N (%) 1931 (26.9%) 546 (22.9%) 1385 (28.9%) <0.001
ESRD (current or prior) 868 (12.1%) 247 (10.3%) 621 (12.9%) 0.001
Received systemic corticosteroid/immunosuppressive/chemotherapy 590 (8.2%) 177 (7.4%) 413 (8.6%) 0.082
Leukemia, lymphoma, metastasis 388 (5.4%) 80 (3.4%) 308 (6.4%) <0.001
Autoimmune diseases* 266 (3.7%) 75 (3.1%) 191 (4%) 0.076
Aplastic anemia and pancytopenia 144 (2.0%) 22 (0.9%) 122 (2.5%) <0.001
Organ transplantation 116 (1.6%) 32 (1.3%) 84 (1.8%) 0.193
HIV/AIDS 55 (0.8%) 31 (1.3%) 24 (0.5%) <0.001
Neutropenia 46 (0.6%) 6 (0.3%) 40 (0.8%) 0.004
Other immunosuppression factors** 17 (0.2%) 4 (0.2%) 13 (0.3%) 0.395
Comorbidity (current or 12 months prior to admission unless noted), N (%)
Hypertension 3585 (49.9%) 1071 (44.9%) 2514 (52.4%) <0.001
Diabetes mellitus by diagnosis code or medications 3440 (47.9%) 936 (39.2%) 2504 (52.2%) <0.001
Diabetic lower extremity infection (current encounter) 1746 (24.3%) 458 (19.2%) 1288 (26.9%) <0.001
Renal dysfunction at baseline 1348 (18.8%) 332 (13.9%) 1016 (21.2%) <0.001
Heart failure 1221 (17.0%) 330 (13.8%) 891 (18.6%) <0.001
Coronary artery disease 1139 (15.9%) 328 (13.7%) 811 (16.9%) 0.001
Complication of electronic internal device (ICD-9 Code = 996.6, current encounter) 1087 (15.1%) 259 (10.9%) 828 (17.3%) <0.001
Chronic obstructive pulmonary disease 815 (11.3%) 250 (10.5%) 565 (11.8%) 0.100
Cardiac dysrhythmias (prior to index encounter) 569 (7.9%) 166 (7%) 403 (8.4%) 0.032
Acute coronary syndrome/angina 534 (7.4%) 144 (6%) 390 (8.1%) 0.001
Cancer 521 (7.3) 110 (4.6%) 411 (8.6%) <0.001
Cerebrovascular disease 283 (3.9%) 81 (3.4%) 202 (4.2%) 0.093
Hematologic dysfunction at baseline 265 (3.7%) 87 (3.6%) 215 (4.5%) 0.096
Cirrhosis/chronic liver disease 198 (2.8%) 45 (1.9%) 153 (3.2%) 0.001
Laboratory values, mean (SD)
Hematocrit (%) 36.7 (6.0) 37.4 (5.7) 36.4 (6.1) <0.001
White blood cell count (k/mm3) 12.8 (8.4) 12.5 (8.3) 12.9 (8.4) 0.048
Serum creatinine (mg/dL) 2.0 (2.3) 1.7 (2.1) 2.1 (2.4) <0.001
Platelet count (k/mm3) 266.8 (119.2) 272.2 (109.3) 264.1 (123.7) 0.015
* Rheumatoid arthritis, multiple sclerosis, psoriasis, Crohn's disease.
** Includes cystic fibrosis, bone marrow transplant, pulmonary tuberculosis, abnormalities of spleen.
Abbreviations: ESRD, end-stage renal disease; HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; ICD-9, International Classification
of Disease; MRSA, methicillin-resistant Staphylococcus aureus; SD, standard deviation.
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(T-5) and 7 (T-7). Using the pre-test probability of
MRSA of 33% (the overall prevalence in our cohort), at
a threshold score of 3 or higher the posterior probability
of having MRSA is 34.5%. Similarly, for the score of 5 it
becomes 43.0%, and for the score of 7 it is 48.2%. Alter-
natively, if the score is below 3, the posterior probability
of having MRSA diminishes to less than 25%.
Discussion
In this large multi-center cohort study, we have demon-
strated that MRSA is present in one-third of all cSSSI
patients hospitalized for their infection. There was a dis-
tinct age difference with regard to the risk for MRSA,
wherein younger age groups were more likely to be
infected with it relative to the older ones. Similarly, the
burdens of comorbidities and risk factors for healthcare-
associated infection were lower in the MRSA-infected
group compared to those harboring non-MRSA. Com-
mensurately, both hospital mortality and LOS among
the MRSA-infected group were lower when compared to
the non-MRSA group. Finally, we developed a bedside
risk score to aid in the early identification of MRSA as a
potential pathogen. Although improving somewhat the
post-test probability of MRSA, the usefulness of the
score may be limited by the high pathogen prevalence in
the cohort.
Over the last decade, the increasing frequency of re-
sistant organisms among persons presenting with infec-
tions from the community prompted a re-evaluation of
the populations at risk for harboring such pathogens.
Out of this effort, the HCA infection definition was born
to signify a patient presenting from the community who
is nevertheless put at risk for resistant pathogens by his/
her ongoing contact with the healthcare system [15].
Some of the commonly acknowledged risk factors for
HCA infection are recent hospitalization, immune sup-
pression, need for hemodialysis and nursing home resi-
dence. Because the HCA risk factors were neither
developed nor validated prospectively, several authors
have expressed concern that such imprecise definition
would lead to over-diagnosis of resistance, and thus
Table 2 MRSA risk prediction score model
Skin Infection, any site
Age ≤ 29 30–39 40–49 50–59 60+ Sub Score =
Points 2 3 2 1 0
Black Race; If true add 1
No Evidence of Diabetes Mellitus (DM) or Presence of
Medication for the Treatment of DM; If true, add 1
No Evidence of Cancer (eg, lymphoma, leukemia):
If true, add 1
No Evidence of Renal Dysfunction:




current Serum Creatinine > 2 mg/dL; if true, add 1
Presence of Cardiac Dysrhythmias Prior to Index
Encounter;If present (if true); add 1
Total =
MRSA=methicillin-resistant S. aureus; ESRD=end-stage renal disease;
WBC=white blood cells.
Figure 1 Model calibration: proportion of patients with MRSA by the score value in development and validation cohorts.
MRSA=methicillin-resistant S. aureus.
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overtreatment, with its sequelae of promoting further re-
sistance development. For example, in a cohort of
patients with HCA pneumonia (HCAP), Shorr et al. cal-
culated the specificity of the HCAP risk factors for a re-
sistant pathogen to be below 50% [17]. In an effort to
sharpen accuracy, the investigators focused on identify-
ing specific risk factors for resistant pathogens overall
and for MRSA individually, with the view to developing
a simple bedside risk score [17,18].
Our findings are important on several accounts. The
risk factors we found that were strongly associated with
the presence of a MRSA infection differed from the
broadly used HCA definition. In fact, HCA was less
likely to be present in the setting of MRSA than non-
MRSA infection. Although this differs from other
reports that found 2/3 of all MRSA cSSSIs to have
underlying HCA risk factors, the discrepancy is likely
due more to the lower prevalence of HCA overall in the
current study rather than to fundamental microbiologic
differences [19]. That is the prior study noted ~75%
prevalence of HCA in the cohort of 717 patients admit-
ted with a cSSSI, while in the current analysis it was only
35%. Given that the previous result came from a single-
center analysis, the current data are more generalizable.
Additionally, although the systematically derived score
performed somewhat better than the consensus defin-
ition, it was far from perfect, thus shielding some, but
not all, of those with susceptible pathogens from expos-
ure to overly broad coverage. A similar finding was
reported by Schreiber et al. in a group of patients with
pneumonia and respiratory failure [20].
In the realm of cSSSI, the evidence-based guideline
recommendations shed limited light on how to evaluate
a patient’s risk for harboring MRSA [21]. Compounding
this difficulty further is the emergence of distinct
community-acquired genotypes: though they require
expanded antimicrobial coverage, their risk factors di-
verge from the traditional HCA paradigm. Although we
were unable to examine the genetic make-up of the
organisms in our study, the finding that MRSA was
more frequent in the younger age groups may be con-
sistent with the high prevalence of CA-MRSA. This
underscores the need for a better risk stratification tool
in this area than the HCA definition alone can provide.
Our current effort extends the findings of previous
investigators on the challenges of identifying resistant
organisms upon presentation and prior to the availability
of culture results. In our study, the HCA definition iden-
tified only 32.0% of patients with MRSA correctly, while
mislabeling an additional 35.5% as having MRSA, thus
potentially prompting a high volume of overuse of
broad-spectrum coverage (Table 4). In contrast, different
values for our MRSA score provide flexibility for balan-
cing sensitivity with specificity, and, therefore the nega-
tive with the positive predictive values. Namely, if
excluding the possibility of MRSA is of primary interest,
then the MRSA score of 2 or higher provides a higher
degree of confidence than the HCA definition, given its
substantially higher negative predictive value. However,
when accuracy in general is sought, it is clear that higher
MRSA scores (e.g., 4 or more) possess better test charac-
teristics than the HCA definition, thus leading to more
targeted prescription and less potential misuse of
antibiotics.
Our study has a number of strengths and limitations.
As a large multicenter cohort representing over 60 US
Table 3 Prevalence of MRSA at different levels of the MRSA score in the dataset
When the MRSA Score is! 0 or 1 2 3 4 5 6 7 or 8 Overall Rate
Percent of Observed 19.9% 24.8% 25.3% 32.5% 45.8% 50.9% 65.4% 33.2%
Patients with MRSA
MRSA=methicillin-resistant S. aureus.










Overall prevalence of patients
with the score value or higher
in the validation set
2 95.2% 7.7% 35.3% 75.3% 93.3%
3 80.2% 30.9% 38.0% 74.7% 72.9%
4** 61.6% 58.6% 44.0% 74.3% 48.4%
5* 44.8% 75.9% 49.6% 72.3% 31.2%
6 17.0% 90.4% 48.3% 67.4% 12.2%
7 or 8 2.8% 99.4% 70.0% 65.9% 1.4%
HCA risk factors 32.0% 64.5% 32.3% 64.3% 34.3%
*MRSA score of 5 or higher is superior to HCA risk factors on all classification metrics.
**MRSA Score of 4 or higher is superior to HCA risk factors on all metrics but specificity.
MRSA=methicillin-resistant S. aureus; HCA=healthcare associated.
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hospitals, it has a high degree of generalizability. At the
same time, as a retrospective observational study it is
subject to a number of threats to validity, including a se-
lection bias. We mitigated the possibility of this by set-
ting a priori cohort definitions and including all
consecutive patients meeting our selection criteria.
Given that we relied on administrative coding to define
our cohort, the study is prone to some degree of mis-
classification. However, the same approach has been
used widely by multiple investigators, and this type of
misclassification is likely to be either minor or non-
differential [11,12,22]. Finally, while we focused on pre-
dictors that had a strong association with MRSA and
were common, it is possible that other variables not in
our database would have yielded a more accurate model,
though we note that the list of predictors examined was
quite comprehensive.
Conclusions
In summary, although our simple bedside score did im-
prove on the specificity of the HCA definition, it left room
for further improvement. Ultimately, what is needed is a
bedside diagnostic tool that can identify MRSA and other
resistant organisms rapidly and with a high degree of ac-
curacy, so as to tailor treatment appropriately. Until such
tools are available, and depending on the local patterns of
resistance, empiric broad-spectrum coverage followed by
prompt de-escalation in response to microbiology data
may need to remain the standard of care.
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